FIGURE 1



PHASE 1: MEDI1/5 Single-agent Dose-escalation and Dose-expansion Arms
Total Subjects = 49 - 67
Dose-escalation Arm: MEDI1/5 Single-agent Cohorts
Cohort -2 5 mg
Cohort -1 10 mg
Cohort 1 20 mg
Cohort 2 100 mg
Cohort 3 300 mg
Cohort 4 1000 mg
Cohort 5 1500 mg
Cycle Length = 21 days; Total Subjects = 24 - 42
Dose-expansion Arm: MEDI1/5 Single-agent Ovarian Cancer Cohorts
Cohort OCE -1 1000 mg
Cohort OCE 1 1500 mg
Cycle Length = 21 days; Total Subjects = 25
PHASE 1b: MEDI1/5 with Bevacizumab or Combination Chemotherapy Dose-escalation Arms
Total Subjects = 57 - 84
Dose-escalation Arm: MEDI1/5 + Bevacizumab Cohorts Q3W Dosing
Cohort MB 1A 100 mg + bevacizumab 15 mg/kg
Cohort MB 2A 300 mg + bevacizumab 15 mg/kg
Cohort MB 3A 1000 mg + bevacizumab 15 mg/kg
Cohort MB 4A 1500 mg + bevacizumab 15 mg/kg
Cycle Length = 21 days; Total Subjects = 15 - 24
Dose-escalation Arm: MEDI1/5 + Bevacizumab Cohorts Q2W Dosing
Cohort MB 1B 60 mg + bevacizumab 10 mg/kg; D1, 15
Cohort MB 2B 200 mg + bevacizumab 10 mg/kg; D1, 15
Cohort MB 3B 600 mg + bevacizumab 10 mg/kg; D1, 15
Cohort MB 4B 1000 mg + bevacizumab 10 mg/kg; D1, 15
Cycle Length = 28 days; Total Subjects = 15 - 24
Dose-escalation Arm: MEDI1/5 + Weekly Paclitaxel Cohorts
Cohort MP1 MEDI1/5 MTD/OBD - 1 ; D1, 15 + paclitaxel 80 mg/m2 ; D1, 8, 15
Cohort MP2 MEDI1/5 MTD/OBD ; D1, 15 + paclitaxel 80 mg/m2 ; D1, 8, 15
Cycle Length = 28 days (essentially 3 weeks on / 1 week off); Total Subjects = 9 - 12
Dose-escalation Arm: MEDI1/5 + Carboplatin/Paclitaxel Cohorts
Cohort MCP1 MEDI1/5 MTD/OBD - 1 ; D1 + carboplatin AUC 5; D1/paclitaxel 175 mg/m2; D1
Cohort MCP2 MEDI1/5 MTD/OBD ; D1 + carboplatin AUC 5; D1/paclitaxel 175 mg/m2; D1
Cycle Length = 21 days; Total Subjects = 9 - 12
Dose-escalation Arm: MEDI1/5 + Gemcitabine/Carboplatin Cohorts
Cohort MGC1 MEDI1/5 MTD/OBD - 1 ; D1 + gemcitabine 1000 mg/m2 ; D1, 8 / carboplatin AUC 4; D1
Cohort MGC2 MEDI1/5 MTD/OBD - 1 ; D1 + gemcitabine 1000 mg/m2 ; D1, 8 / carboplatin AUC 4; D1
Cycle Length = 21 days; Total Subjects = 9 - 12
Two Phase 1/1b Dose-expansion Arms in Malignant Glioma:
MEDI1/5 + bevacizumab cohorts
(15-60 subjects each)
Q2W dosing
Cohort TT1A (Bevacizumab naïve) 1000 mg + bevacizumab 10 mg/kg; D1, 15
Cohort TT2A (Bevacizumab refractory) 1000 mg + bevacizumab 10 mg/kg; D1, 15

FIGURE 2A



MED1/5 Conc (µg/mL)
1000
100
10
1
0.1
0.01
0
7
14
21
Time (Day)
5 mg Q3W (n=3)
10 mg Q3W (n=2)
20 mg Q3W (n=5-6)
100 mg Q3W (n=2-7)
300 mg Q3W (n=3-6)
1000 mg Q3W (n=3-9)
1500 mg Q3W (n=4-6)

FIGURE 2B



Q2W
MEDI1/5 Conc (μg/mL)
1000
100
10
1
0.1
0.01
0
7
14
21
Time (day)
60 mg Q2W (n=7)
200 mg Q2W (n=3)
600 mg Q2W (n=7–10)
1000 mg Q2W (n=2–6)

FIGURE 3



5 mg Q3W (n=2-4)
10 mg Q3W (n=2-3)
20 mg Q3W (n=5-7)
100 mg Q3W (n=5-7)
300 mg Q3W (n=2-5)
1000 mg Q3W (n=7-9)
1500 mg Q3W (n=11-15)
Total Angz (ng/mL)
10000
1000
100
10
1
0
7
14
21
Time (Day)

FIGURE 4




FIGURE 5







FIGURE 6



Month 19
(C4D8)




Month 18
(C2D23)



Month 15

FIGURE 7



Month 19 (C4D8)

Month 18 (C2D23)

Month 15